ConductScience.org, home
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
API referenceFor AI assistants

Trial · NCT02737475

Participant flow81

How many started, completed or left each group, period by period.

1 to 20 of 81

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDEscalation Part 1: BMS 20 mg Q2W4
Overall StudySTARTEDEscalation Part 1: BMS 40 mg Q2W4
Overall StudySTARTEDEscalation Part 1: BMS 80 mg Q2W4
Overall StudySTARTEDEscalation Part 1: BMS 160 mg Q2W4
Overall StudySTARTEDEscalation Part 1: BMS 320 mg Q2W4
Overall StudySTARTEDEscalation Part 2 BMS 20 mg + Nivo 240 mg Q2W7
Overall StudySTARTEDEscalation Part 2: BMS 40 mg + Nivo 240 mg Q2W8
Overall StudySTARTEDEscalation Part 2: BMS 80 mg + Nivo 240 mg Q2W12
Overall StudySTARTEDEscalation Part 2: BMS 160 mg + Nivo 240 mg Q2W8
Overall StudySTARTEDEscalation Part 2: BMS 320 mg + Nivo 240 mg Q2W8
Overall StudySTARTEDEscalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W4
Overall StudySTARTEDEscalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W10
Overall StudySTARTEDEscalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W7
Overall StudySTARTEDEscalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W8
Overall StudySTARTEDEscalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W6
Overall StudySTARTEDExpansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC)18
Overall StudySTARTEDSchedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W12
Overall StudySTARTEDSchedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W6
Overall StudySTARTEDSafety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC)7
Overall StudySTARTEDExpansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC)1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02737475/flow

API referenceFor AI assistants